MAIL STOP AMENDMENT

Attorney Docket No.: 26430U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

NISHIBE, et al.

Confirmation No. 5312

Serial No: 10/519,484

Group Art Unit: 1615

Filed:

July 21, 2005

Examiner: PALENIK, Jefferey T.

For: CICLESONIDE-CONTAINING STERILE AQUEOUS SUSPENSION

TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- 1) Transmittal letter;
- 2) Response and Amendment (8 pages);

Please charge any required fee, or credit any overpayment, in connection with this matter to deposit Account No. 14-0112.

> Respectfully submitted, The Nath Law Group, PLLC

Date: March 17, 2008

Gary M. Nath

Registration No. 26,965

Joshua B. Goldberg

Registration No. 44,126

Charles D. Niebylski

Registration No. 46,116


Customer No. 34375

THE NATH LAW GROUP, PLLC

112 South West Street Alexandria, VA 22314

Tel: (703) 548-6284 Fax: (703) 683-8396

JBG/CDN\ROA3.TL.doc



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

NISHIBE, et al.

Confirmation No. 5312

Serial No: 10/519,484

Group Art Unit: 1615

Filed: July 21, 2005

Examiner: PALENIK, Jefferey T.

For: CICLESONIDE-CONTAINING STERILE AQUEOUS SUSPENSION

RESPONSE AND AMENDMENT UNDER 37 C.F.R. §1.111

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This is a full and complete response to the Office Action having a mailing date of December 18, 2007. The three month shortened statutory period to respond to the Office Action was set to expire March 18, 2008, thus this response is timely filed.

In view of the following amendments and remarks, the Applicant respectfully requests that the Examiner reconsider and withdraw the outstanding rejections and allow this application.

Amendments to the Abstract begin on page 2 of this paper.

Amendments to the Claims are reflected in a listing of claims, which begins on page 3 of this paper.

Remarks/Arguments begin on page 5 of this paper.